Introducing our newest product, Valganciclovir Hcl, a powerful antiviral medication used to treat cytomegalovirus (CMV) retinitis in patients with AIDS. Valganciclovir Hcl is an oral prodrug of ganciclovir, a potent antiviral agent that inhibits the replication of CMV. This medication is a breakthrough in the treatment of CMV retinitis, a potentially blinding condition that affects individuals with compromised immune systems. Valganciclovir Hcl is available in tablet form, making it convenient and easy to administer. With once-daily dosing, this medication offers improved adherence and convenience for patients undergoing treatment for CMV retinitis. The active ingredient, valganciclovir, is rapidly converted to ganciclovir in the body, ensuring high bioavailability and efficacy in fighting CMV infection. Our product is supported by extensive clinical research and has been shown to significantly reduce the progression of CMV retinitis, leading to improved visual outcomes for patients. It has also demonstrated a favorable safety profile, making it a reliable and well-tolerated treatment option. We are proud to offer Valganciclovir Hcl as an important advancement in the management of CMV retinitis, providing hope and improved quality of life for patients affected by this devastating condition. With its proven efficacy, convenience, and safety, Valganciclovir Hcl is set to make a meaningful impact on the treatment of CMV retinitis.

JDK, a company with a professional team equipped with specialized and interdisciplinary technical talents, has been focusing on the development of pharmaceutical intermediates and basic chemicals. The